Published in Law and Health Weekly, July 15th, 2006
"While we continue to make progress at Enzo Therapeutics and in the growth of our intellectual property base, price competition and continuing litigation expenses impacted operating results during the third quarter," said Barry Weiner, president. "Our focus remains on growing the company, and broadening our operating scope with new products."
The recent addition of new, highly experienced...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Law and Health Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.